The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak
Open accessAbstract
BACKGROUND: The outcome is reported of a prospective uncontrolled study based on a stepwise treatment protocol during an outbreak of severe acute respiratory syndrome (SARS) in Hong Kong. METHOD: One hundred and thirty eight patients were treated with broad spectrum antibiotics, a combination of ribavirin and low dose corticosteroid, and then intravenous high dose methylprednisolone according to responses. Sustained response to treatment was defined as (1) defervescence for > or =4 consecutive days, (2) resolution of lung consolidation by >25%, and (3) oxygen independence by the fourth day without fever. Patients with defervescence who achieved either criterion 2 or 3 were classified as partial responders. Patients who fell short of criteria 2 and 3 were non-responders. RESULTS: Laboratory confirmation of SARS coronavirus infection was established in 132 (95.7%). None responded to antibiotics but 25 (18.1%) responded to ribavirin + low dose corticosteroid. Methylprednisolone was used in 107 patients, of whom 95 (88.8%) responded favourably. Evidence of haemolytic anaemia was observed in 49 (36%). A high level of C-reactive protein at presentation was the only independent predictor for use of methylprednisolone (odds ratio 2.18 per 10 mg/dl increase, 95% confidence interval 1.12 to 4.25, p = 0.02). Thirty seven patients (26.8%) required admission to the intensive care unit and 21 (15.2%) required invasive mechanical ventilation. There were 15 deaths (mortality rate 10.9%), most with significant co-morbidities, whereas 122 (88.4%) had been discharged home 4 months after the outbreak onset. CONCLUSION: The use of high dose pulse methylprednisolone during the clinical course of a SARS outbreak was associated with clinical improvement, but randomised controlled trials are needed to ascertain its efficacy in this condition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200005043421801 · Cited by 12,941
Acute-Phase Proteins and Other Systemic Responses to Inflammation
Gabay, C., & Kushner, I. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400607 · Cited by 6,734
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574
Effect of prone positioning on the survival of patients with acute respiratory failure.
Gattinoni, L., Tognoni, G., Pesenti, A., Taccone, P., Mascheroni, D., Labarta, V., Malacrida, R., Di Giulio, P., Fumagalli, R., Pelosi, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010043 · Cited by 1,271
Cheung, C., Poon, L., Lau, A., Luk, W., Lau, Y., Shortridge, K., Gordon, S., Guan, Y., & Peiris, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11772-7 · Cited by 889
Cited by
SARS: systematic review of treatment effects
Stockman, L. J., Bellamy, R., & Garner, P. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030343 · Cited by 1,217
Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection
Cheng, V. C. C., Lau, S. K. P., Woo, P. C. Y., & Yuen, K. Y. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00023-07 · Cited by 1,192
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update
Pal, M., Berhanu, G., Desalegn, C., & Kandi, V. (2020) · Cureus · doi:10.7759/cureus.7423 · Cited by 830
Lee, N., Allen Chan, K. C., Hui, D. S., Ng, E. K. O., Wu, A., Chiu, R. W. K., Wong, V. W. S., Chan, P. K. S., Wong, K. T., Wong, E., et al. (2004) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.07.006 · Cited by 636
Self-citationHui, D. S. (2005) · Thorax · doi:10.1136/thx.2004.030205 · Cited by 531
NGAI, J. C., KO, F. W., NG, S. S., TO, K., TONG, M., & HUI, D. S. (2010) · Respirology · doi:10.1111/j.1440-1843.2010.01720.x · Cited by 510
Severe Acute Respiratory Syndrome
Hui, D. S. C., & Zumla, A. (2019) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2019.07.001 · Cited by 506
Omrani, A. S., Saad, M. M., Baig, K., Bahloul, A., Abdul-Matin, M., Alaidaroos, A. Y., Almakhlafi, G. A., Albarrak, M. M., Memish, Z. A., & Albarrak, A. M. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70920-x · Cited by 493
Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques
Falzarano, D., de Wit, E., Rasmussen, A. L., Feldmann, F., Okumura, A., Scott, D. P., Brining, D., Bushmaker, T., Martellaro, C., Baseler, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3362 · Cited by 445
Edalatifard, M., Akhtari, M., Salehi, M., Naderi, Z., Jamshidi, A., Mostafaei, S., Najafizadeh, S. R., Farhadi, E., Jalili, N., Esfahani, M., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02808-2020 · Cited by 410
Chan, K. W., Wong, V. T., & Tang, S. C. W. (2020) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x20500378 · Cited by 398
Hui, D. S., Wong, K. T., Ko, F. W., Tam, L. S., Chan, D. P., Woo, J., & Sung, J. J. Y. (2005) · Chest · doi:10.1378/chest.128.4.2247 · Cited by 368
Self-citationEarly Corticosteroids in Severe Influenza A/H1N1 Pneumonia and Acute Respiratory Distress Syndrome
Brun-Buisson, C., Richard, J.-C. M., Mercat, A., Thiébaut, A. C. M., & Brochard, L. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201101-0135oc · Cited by 338
Al-Tawfiq, J. A., Momattin, H., Dib, J., & Memish, Z. A. (2014) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2013.12.003 · Cited by 322
Molecular pathology of emerging coronavirus infections
Gralinski, L. E., & Baric, R. S. (2015) · The Journal of Pathology · doi:10.1002/path.4454 · Cited by 319
Current pharmacological treatments for COVID‐19: What's next?
Scavone, C., Brusco, S., Bertini, M., Sportiello, L., Rafaniello, C., Zoccoli, A., Berrino, L., Racagni, G., Rossi, F., & Capuano, A. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15072 · Cited by 283
Hasan, S. S., Capstick, T., Ahmed, R., Kow, C. S., Mazhar, F., Merchant, H. A., & Zaidi, S. T. R. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1804365 · Cited by 283
Treatment of Severe Acute Respiratory Syndrome With Glucosteroids
Chen, R.-C., Tang, X.-P., Tan, S.-Y., Liang, B.-L., Wan, Z.-Y., Fang, J.-Q., & Zhong, N. (2006) · Chest · doi:10.1378/chest.129.6.1441 · Cited by 274
Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin
Falzarano, D., de Wit, E., Martellaro, C., Callison, J., Munster, V. J., & Feldmann, H. (2013) · Scientific Reports · doi:10.1038/srep01686 · Cited by 273
Li, H., Chen, C., Hu, F., Wang, J., Zhao, Q., Gale, R. P., & Liang, Y. (2020) · Leukemia · doi:10.1038/s41375-020-0848-3 · Cited by 265
Methods for estimating the case fatality ratio for a novel, emerging infectious disease
Ghani, A. C., Donnelly, C. A., Cox, D. R., Griffin, J. T., Fraser, C., Lam, T. H., Ho, L. M., Chan, W. S., Anderson, R. M., Hedley, A. J., et al. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi230 · Cited by 252
Acute respiratory distress syndrome and pneumonia: a comprehensive review of clinical data
Bauer, T. T., Ewig, S., Rodloff, A. C., & Muller, E. E. (2006) · Clinical Infectious Diseases · doi:10.1086/506430 · Cited by 151
Morgenstern, C., Rawson, T., Routledge, I., Kont, M., Imai-Eaton, N., Skarp, J., Doohan, P., McCain, K., Johnson, R., Unwin, H. J. T., et al. (2025) · The Lancet Microbe · doi:10.1016/j.lanmic.2025.101144 · Cited by 6
Metadata
- Authors
- Sung, J. J. Y.
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 2004-05-01
- Volume
- 59
- Issue
- 5
- Pages
- 414-420
- ISSN
- 0040-6376 (ISSN-L)
- OpenAlex
- W2166726995
- Cited by
- 185
- References
- 5
- FWCI
- 10.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.